Literature DB >> 19339779

Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network.

Johannes Kornhuber1, Klaus Schmidtke, Lutz Frolich, Robert Perneczky, Stefanie Wolf, Harald Hampel, Frank Jessen, Isabella Heuser, Oliver Peters, Markus Weih, Holger Jahn, Christian Luckhaus, Michael Hüll, Hermann-Josef Gertz, Johannes Schröder, Johannes Pantel, Otto Rienhoff, Susanne A Seuchter, Eckart Rüther, Fritz Henn, Wolfgang Maier, Jens Wiltfang.   

Abstract

BACKGROUND: The German Dementia Competence Network (DCN) has established procedures for standardized multicenter acquisition of clinical, biological and imaging data, for centralized data management, and for the evaluation of new treatments.
METHODS: A longitudinal cohort study was set up for patients with mild cognitive impairment (MCI), patients with mild dementia and control subjects. The aims were to establish the diagnostic, differential diagnostic and prognostic power of a range of clinical, laboratory and imaging methods. Furthermore, 2 clinical trials were conducted with patients suffering from MCI and mild to moderate Alzheimer's Disease (AD). These trials aimed at evaluating the efficacy and safety of the combination of galantamine and memantine versus galantamine alone.
RESULTS: Here, we report on the scope and projects of the DCN, the methods that were employed, the composition and flow within the diverse groups of patients and control persons and on the clinical and neuropsychological baseline characteristics of the group of 2,113 subjects who participated in the observational and clinical trials.
CONCLUSION: These data have an impact on the procedures for the early and differential clinical diagnosis of dementias, the current standard treatment of AD as well as on future clinical trials in AD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19339779     DOI: 10.1159/000210388

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  31 in total

1.  Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment.

Authors:  K Blennow; G De Meyer; O Hansson; L Minthon; A Wallin; H Zetterberg; P Lewczuk; H Vanderstichele; E Vanmechelen; J Kornhuber; J Wiltfang; I Heuser; W Maier; C Luckhaus; E Rüther; M Hüll; H Jahn; H J Gertz; L Frölich; H Hampel; R Pernetzki
Journal:  J Nutr Health Aging       Date:  2009-03       Impact factor: 4.075

2.  PLD3 in non-familial Alzheimer's disease.

Authors:  Stefanie Heilmann; Dmitriy Drichel; Jordi Clarimon; Victoria Fernández; André Lacour; Holger Wagner; Mathias Thelen; Isabel Hernández; Juan Fortea; Montserrat Alegret; Rafael Blesa; Ana Mauleón; Maitée Rosende Roca; Johannes Kornhuber; Oliver Peters; Reinhard Heun; Lutz Frölich; Michael Hüll; Michael T Heneka; Eckart Rüther; Steffi Riedel-Heller; Martin Scherer; Jens Wiltfang; Frank Jessen; Tim Becker; Lluís Tárraga; Mercè Boada; Wolfgang Maier; Alberto Lleó; Agustin Ruiz; Markus M Nöthen; Alfredo Ramirez
Journal:  Nature       Date:  2015-04-02       Impact factor: 49.962

3.  Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts.

Authors:  Nienke M E Scheltens; Betty M Tijms; Teddy Koene; Frederik Barkhof; Charlotte E Teunissen; Steffen Wolfsgruber; Michael Wagner; Johannes Kornhuber; Oliver Peters; Brendan I Cohn-Sheehy; Gil D Rabinovici; Bruce L Miller; Joel H Kramer; Philip Scheltens; Wiesje M van der Flier
Journal:  Alzheimers Dement       Date:  2017-04-17       Impact factor: 21.566

4.  SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease.

Authors:  Alfredo Ramirez; Wiesje M van der Flier; Christine Herold; David Ramonet; Stefanie Heilmann; Piotr Lewczuk; Julius Popp; André Lacour; Dmitriy Drichel; Eva Louwersheimer; Markus P Kummer; Carlos Cruchaga; Per Hoffmann; Charlotte Teunissen; Henne Holstege; Johannes Kornhuber; Oliver Peters; Adam C Naj; Vincent Chouraki; Céline Bellenguez; Amy Gerrish; Reiner Heun; Lutz Frölich; Michael Hüll; Lara Buscemi; Stefan Herms; Heike Kölsch; Philip Scheltens; Monique M Breteler; Eckart Rüther; Jens Wiltfang; Alison Goate; Frank Jessen; Wolfgang Maier; Michael T Heneka; Tim Becker; Markus M Nöthen
Journal:  Hum Mol Genet       Date:  2014-07-15       Impact factor: 6.150

Review 5.  Cerebrospinal fluid biomarkers of Alzheimer's disease.

Authors:  Anne M Fagan; David M Holtzman
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

6.  Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia.

Authors:  Rosalinde E R Slot; Sietske A M Sikkes; Johannes Berkhof; Henry Brodaty; Rachel Buckley; Enrica Cavedo; Efthimios Dardiotis; Francoise Guillo-Benarous; Harald Hampel; Nicole A Kochan; Simone Lista; Tobias Luck; Paul Maruff; José Luis Molinuevo; Johannes Kornhuber; Barry Reisberg; Steffi G Riedel-Heller; Shannon L Risacher; Susanne Roehr; Perminder S Sachdev; Nikolaos Scarmeas; Philip Scheltens; Melanie B Shulman; Andrew J Saykin; Sander C J Verfaillie; Pieter Jelle Visser; Stephanie J B Vos; Michael Wagner; Steffen Wolfsgruber; Frank Jessen; Wiesje M van der Flier
Journal:  Alzheimers Dement       Date:  2018-12-13       Impact factor: 21.566

7.  The rare TREM2 R47H variant exerts only a modest effect on Alzheimer disease risk.

Authors:  Basavaraj V Hooli; Antonio R Parrado; Kristina Mullin; Wai-Ki Yip; Tian Liu; Johannes T Roehr; Dandi Qiao; Frank Jessen; Oliver Peters; Tim Becker; Alfredo Ramirez; Christoph Lange; Lars Bertram; Rudolph E Tanzi
Journal:  Neurology       Date:  2014-09-03       Impact factor: 9.910

8.  Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects.

Authors:  Piotr Lewczuk; Johannes Kornhuber; Jon B Toledo; John Q Trojanowski; Malgorzata Knapik-Czajka; Oliver Peters; Jens Wiltfang; Leslie M Shaw
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 9.  Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimer's disease and other neurodegenerative dementias.

Authors:  J Genius; H Klafki; J Benninghoff; H Esselmann; J Wiltfang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2012-09-18       Impact factor: 5.270

10.  Neurokinin3 receptor as a target to predict and improve learning and memory in the aged organism.

Authors:  Maria A de Souza Silva; Bernd Lenz; Andrea Rotter; Teresa Biermann; Oliver Peters; Alfredo Ramirez; Frank Jessen; Wolfgang Maier; Michael Hüll; Johannes Schröder; Lutz Frölich; Stefan Teipel; Oliver Gruber; Johannes Kornhuber; Joseph P Huston; Christian P Müller; Sandra Schäble
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.